Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

753 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95.
Woessmann W, Seidemann K, Mann G, Zimmermann M, Burkhardt B, Oschlies I, Ludwig WD, Klingebiel T, Graf N, Gruhn B, Juergens H, Niggli F, Parwaresch R, Gadner H, Riehm H, Schrappe M, Reiter A; BFM Group. Woessmann W, et al. Among authors: graf n. Blood. 2005 Feb 1;105(3):948-58. doi: 10.1182/blood-2004-03-0973. Epub 2004 Oct 14. Blood. 2005. PMID: 15486066 Free article. Clinical Trial.
[NHL-BFM 90 therapy study in treatment of malignant non-Hodgkin's lymphomas in children and adolescents. Part 2: An intermediate term analysis of the non-B-NHL therapy group. BFM Study group].
Reiter A, Schrappe M, Yakisan E, Sauter S, Henzler D, Zimmermann M, Graf N, Fengler R, Kühl J, Fleischhack G, et al. Reiter A, et al. Among authors: graf n. Klin Padiatr. 1994 Jul-Aug;206(4):234-41. doi: 10.1055/s-2008-1046609. Klin Padiatr. 1994. PMID: 7967419 Clinical Trial. German.
Down's syndrome in childhood acute lymphoblastic leukemia: clinical characteristics and treatment outcome in four consecutive BFM trials. Berlin-Frankfurt-Münster Group.
Dördelmann M, Schrappe M, Reiter A, Zimmermann M, Graf N, Schott G, Lampert F, Harbott J, Niemeyer C, Ritter J, Dörffel W, Nessler G, Kühl J, Riehm H. Dördelmann M, et al. Among authors: graf n. Leukemia. 1998 May;12(5):645-51. doi: 10.1038/sj.leu.2400989. Leukemia. 1998. PMID: 9593260
IDA-FLAG (idarubicin, fludarabine, cytarabine, G-CSF), an effective remission-induction therapy for poor-prognosis AML of childhood prior to allogeneic or autologous bone marrow transplantation: experiences of a phase II trial.
Fleischhack G, Hasan C, Graf N, Mann G, Bode U. Fleischhack G, et al. Among authors: graf n. Br J Haematol. 1998 Aug;102(3):647-55. doi: 10.1046/j.1365-2141.1998.00836.x. Br J Haematol. 1998. PMID: 9722289 Free article. Clinical Trial.
Definition of a standard-risk group in children with AML.
Creutzig U, Zimmermann M, Ritter J, Henze G, Graf N, Löffler H, Schellong G. Creutzig U, et al. Among authors: graf n. Br J Haematol. 1999 Mar;104(3):630-9. doi: 10.1046/j.1365-2141.1999.01304.x. Br J Haematol. 1999. PMID: 10086807 Free article.
Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: A report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90.
Reiter A, Schrappe M, Tiemann M, Ludwig WD, Yakisan E, Zimmermann M, Mann G, Chott A, Ebell W, Klingebiel T, Graf N, Kremens B, Müller-Weihrich S, Plüss HJ, Zintl F, Henze G, Riehm H. Reiter A, et al. Among authors: graf n. Blood. 1999 Nov 15;94(10):3294-306. Blood. 1999. PMID: 10552938 Free article. Clinical Trial.
753 results